The promises of gene therapy have been slow to reach the public for many reasons.  Technologies conceived in the 1980’s had a substantial regulatory and proof-of-concept road ahead of them, leading to slow development and deployment.  One of the major issues is that these therapies were designed for humans, where ethics concerns and regulation are a challenge to navigate.  However, it is possible to demonstrate efficacy in animals.  Emily Mullin is the Associate Editor at MIT Technology Review.  She recently covered the application of gene therapy to animals, and now describes its application in veterinary capacities where regulation is much lower than in human therapy.Follow Emily on Twitter:  @emilylmullinRead her work at MIT Technology Review# COLABRATalking Biotech is brought to you by Colabra – an R&D platform that brings your lab’s world-changing research together in one shared space. Learn more at https://www.colabra.app/# TALKING BIOTECHTwitter: https://twitter.com/talkingbiotechWebsite: https://www.colabra.app/podcasts/talking-biotech/Instagram: https://www.instagram.com/colabrahqThe Talking Biotech podcast is distinct from Dr. Kevin Folta's teaching and research roles at the University of Florida. The views expressed on the show are those of Dr. Folta and his guests, and do not reflect the opinions of the university or Colabra.